Answers are grounded in this paper and cite their sources.
Summit discusses bioelectronic therapies and neuromodulation advancements for varied communities, implying broad access benefits.
The Sixth Bioelectronic Medicine Summit took place on March 4 and 5, 2025 at the Garden City Hotel in New York, and was co-hosted by the Feinstein Institutes for Medical Research (FIMR), Northwell Health and the University of Minnesota. The Summit brought together speakers and attendees from academia, medicine and industry to discuss the evolving landscape of neuromodulation and bioelectronic therapeutics. This year’s Summit was titled “Neurotechnologies for Individuals and Communities” and emphasized approaches that consider differences between subjects to deliver precision neuromodulation therapies, as well as approaches that expand the therapeutic footprint of neuromodulation to underserved populations and communities. The Summit included sessions covering basic and translational research, device development and commercialization, and emerging clinical applications. This meeting report summarizes the major events from the two days of the Summit, including keynote addresses, scientific sessions, discussion panels, award presentations, and sponsored talks.
No takes yet. Share an insight, caveat, or question.
Bahadir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: